364 filings
Page 3 of 19
8-K
7o9a04r
5 Aug 21
BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones
7:06am
8-K
w2k188 gga9
3 Aug 21
Departure of Directors or Certain Officers
5:19pm
8-K
p7hyfsvudord776r oz
28 Jul 21
BioCryst Appoints Vincent Milano to Board of Directors
7:09am
8-K
wg3fbh3p p4bc7ilqod
3 Jun 21
BioCryst Launches ORLADEYO™ (berotralstat) in Germany
7:06am
8-K
ubq1n74b dmaa5
26 May 21
Departure of Directors or Certain Officers
4:26pm
8-K
c5uzab6c5caq 3f1
12 May 21
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
9:45am
8-K
1of50c
6 May 21
BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones
7:09am
8-K
1e9nonr3ye1qmnpjw
30 Apr 21
Regulation FD Disclosure
10:57am
8-K
mrkr3hle9i7zp40
14 Apr 21
BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
8:21am
8-K
f032yq21y8bkweiv0
26 Mar 21
Regulation FD Disclosure
2:02pm
8-K
kk2e0fh lyk3eowhtm38
22 Mar 21
Regulation FD Disclosure
8:07am
8-K
eq7ct8 38
18 Mar 21
Regulation FD Disclosure
4:41pm
8-K
pfdsw
2 Mar 21
Regulation FD Disclosure
7:07am
8-K
7usnd05x gfnoyo68v
25 Feb 21
Regulation FD Disclosure
4:40pm
8-K
zy4kd3mnyn5 4i9jb1
25 Feb 21
BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
7:05am
8-K
uabpb
3 Feb 21
Regulation FD Disclosure
7:06am
8-K
qr3j3 qhd9jjw
22 Jan 21
BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema
7:12am
8-K
yws 4u3wl9pjuu9uxsu7
22 Dec 20
Regulation FD Disclosure
8:16am
8-K
dzplp9 11unj
22 Dec 20
BioCryst Provides Update on Galidesivir Program
7:03am
8-K
ohvrk9nm9z4ya4 go3u
21 Dec 20
BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
7:05am